ArticleClinical epigenetics2025
Accelerating epigenetic age in right-sided colon cancer predicts a favorable outcome.
Article in Clinical epigenetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundDNA methylation age, referred to as 'epigenetic age, epiAge' is an accurate biomarker for aging, including cancer. As a well established age-associated disease, colorectal cancer (CRC) is a highly heterogeneous cancer and can be divided into left-sided colon cancer (LCC), right-sided colon cancer (RCC) and rectal cancer according to the anatomical location of the tumor. However, the association of epigenetic age acceleration (EAA) with CRC tumor location, clinical characteristics, and patient outcomes remain to be clarified.
methodsA total of 548 samples were collected for epiAge estimation, including 192 samples consisting of 96 CRC tumors and 96 matched normal tissues from GSE77718 and 356 CRC tumors from The Cancer Genome Atlas (TCGA). EpiAge were computed using four different epiAge models (Horvath2013, PhenoAge, ZhangQ2019, and EpiTOC). EpiAge and EAA were compared between LCC and RCC. Log rank test was used to assess the association of EAA with LCC and RCC survival.
resultsA significantly older epiAge in the RCC than LCC was observed (P = 0.00025) but not in normal colon tissues. In addition, compared with LCC, EAA was enhanced in female and microsatellite instability-high RCC samples. Meanwhile, we found that epiAge decreased continuously from RCC stage I to stage IV. In contrast, in LCC, stage I had the most serious epiAge deceleration (stage I: - 8.9; stage II: - 1.71; stage III: - 4.91; stage IV: - 4.67). Further, EAA is significantly and negatively or positively associated with RCC and LCC mortality, respectively.
conclusionsOverall, our results suggest that EAA may be a useful biomarker for gaining a deeper understanding of CRC high heterogeneity from a biological aging perspective and will facilitate prognostic judgement and targeted treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.